Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study.

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Personalized Medicine Pub Date : 2024-12-22 DOI:10.3390/jpm14121169

Nicoletta Bernardini, Annunziata Dattola, Raimondo Rossi, Gianluca Pagnanelli, Paolo Amerio, Laura Atzori, Cristina Mugheddu, Viviana Lora, Domenico Giordano, Lucia Finistauri Guacci, Severino Persechino, Antonio Giovanni Richetta, Nevena Skroza, Concetta Potenza

{"title":"Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study.","authors":"Nicoletta Bernardini, Annunziata Dattola, Raimondo Rossi, Gianluca Pagnanelli, Paolo Amerio, Laura Atzori, Cristina Mugheddu, Viviana Lora, Domenico Giordano, Lucia Finistauri Guacci, Severino Persechino, Antonio Giovanni Richetta, Nevena Skroza, Concetta Potenza","doi":"10.3390/jpm14121169","DOIUrl":null,"url":null,"abstract":"Background: the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. Methods: this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. Results: PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. Conclusions: overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 12","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680027/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14121169","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. Methods: this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. Results: PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. Conclusions: overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.

查看原文本刊更多论文

斑块型银屑病患者从Ixekizumab切换到Secukinumab的疗效和安全性：一项多中心回顾性研究

背景：本多中心回顾性研究旨在评估斑块型银屑病患者在白介素- 17a （IL-17A）抑制剂之间切换的疗效和安全性，特别是从ixekizumab切换到secukinumab。方法：本研究纳入了11例患者（6男5女），这些患者之前接受了ixekizumab，然后切换到secukinumab。患者的PASI、DLQI和疼痛VAS（银屑病关节炎患者）在第16、24、54和98周进行评估。结果：10例患者（91%）在第24周达到PASI-90。1例患者在第98周出现二次secukinumab治疗失败。无不良事件报告。结论：总体而言，大多数患者对secukinumab有良好的反应，这表明对于对ixekizumab反应不足或无效的患者，secukinumab可能是一种有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Personalized Medicine Medicine-Medicine (miscellaneous)

CiteScore

4.10

自引率

0.00%

发文量

1878

审稿时长

11 weeks

期刊介绍： Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.